Ashland(US:ASH)2025-11-05 15:00Q4 FY25 Performance - Sales decreased by 8% to $478 million compared to Q4 FY24, but decreased by only 1% compared to the portfolio reset baseline of $484 million[15, 24] - Adjusted EBITDA increased by 110 bps to 249%, but decreased by 4% to $119 million compared to Q4 FY24[15] - Adjusted EPS decreased by 14% to $108[15] Business Unit Performance - Life Sciences sales decreased by 10% to $173 million, but decreased by only 2% compared to the reset results of $177 million; EBITDA margin increased by 260 bps to 318%[25] - Personal Care sales decreased by 7% to $151 million, but increased by 5% compared to the reset results of $143 million; EBITDA margin decreased by 50 bps to 285%[31] - Specialty Additives sales decreased by 9% to $131 million, but decreased by 6% compared to the reset results of $140 million; EBITDA margin increased by 200 bps to 221%[34] - Intermediates sales decreased by 8% to $33 million; EBITDA margin decreased by 1260 bps to 152%[28] Strategic Initiatives & Outlook - The company expects full-year fiscal 2026 sales to be between $1835 million and $1905 million, and adjusted EBITDA to be between $400 million and $430 million[46] - The company is targeting approximately $30 million in savings from restructuring and manufacturing optimization[47] - The company aims to achieve approximately $15 million in sales growth through innovation and approximately $20 million in sales growth through globalization initiatives[47] Financial Position - The company has approximately $08 billion in cash and revolver availability[72] - The company's net debt is $1169 million, with a net leverage of 29x[72]